Evidence map›Paper›PMID 35918574›Full record

ArticleNeurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology2022

Hypogammaglobulinemia is associated with reduced antibody response after anti-SARS-CoV-2 vaccination in MS patients treated with antiCD20 therapies.

Angelo Bellinvia, Maria Grazia Aprea, Emilio Portaccio, Luisa Pastò, Lorenzo Razzolini, Mattia Fonderico, Ilaria Addazio, Matteo Betti, Maria Pia Amato

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.4field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 5 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Angelo Bellinvia *NEUROFARBA Department, University of Florence, Largo Palagi, 1, 50139, Florence, Italy. angelo.bellinvia@unifi.it.ORCID http://orcid.org/0000-0001-9889-9058
Maria Grazia Aprea *NEUROFARBA Department, University of Florence, Largo Palagi, 1, 50139, Florence, Italy.
Emilio PortaccioNEUROFARBA Department, University of Florence, Largo Palagi, 1, 50139, Florence, Italy.
Luisa PastòNEUROFARBA Department, University of Florence, Largo Palagi, 1, 50139, Florence, Italy.
Lorenzo RazzoliniNEUROFARBA Department, University of Florence, Largo Palagi, 1, 50139, Florence, Italy.
Mattia FondericoNEUROFARBA Department, University of Florence, Largo Palagi, 1, 50139, Florence, Italy.
Ilaria AddazioNEUROFARBA Department, University of Florence, Largo Palagi, 1, 50139, Florence, Italy.
Matteo BettiNEUROFARBA Department, University of Florence, Largo Palagi, 1, 50139, Florence, Italy.
Maria Pia AmatoNEUROFARBA Department, University of Florence, Largo Palagi, 1, 50139, Florence, Italy.
University of Florence · ITDon Carlo Gnocchi Foundation · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCOVID-19 vaccination is highly recommended to multiple sclerosis (MS) patients. Little is known about the role of patients' clinical and demographic characteristics in determining antibody response.

methodsWe evaluated safety and efficacy of anti-SARS-CoV-2 vaccines on 143 included MS patients. Then, we analyzed antibody titer in a subgroup, assessing clinical and demographic variables associated with protection and antibody titer.

resultsAfter completing the vaccination cycle, the rate of local adverse events was similar after the first and second dose. A higher proportion of systemic AEs was reported after the second dose (65.7% vs 24.5% after the first dose). Antibody response was evaluated in 97 patients. Higher EDSS (OR 0.6, 95% CI 0.4-0.9, p = 0.006) and treatment with antiCD20 (OR 0.02, 95% CI 0.003-0.098, p 0.001) were associated with a lower chance of having an efficacious response. Higher weight was associated with higher Ab titer (β = 15.2, 95% CI 2.8-27.6, p = 0.017), while treatment with antiCD20 with lower titers (β =  - 1092.3, 95% CI - 1477.4 to - 702.2, p < 0.001). In patients treated with antiCD20, hypogammaglobulinemia (β - 543, 95% CI - 1047.6 to - 39.1, p = 0.036) and treatment duration (β - 182, 95% CI - 341.4 to - 24.3, p = 0.027) were associated with lower Ab titer.

conclusionOur study confirms that COVID-19 vaccination in MS patient is safe and effective in preventing symptomatic COVID-19 and should be recommended to all patients. Moreover, we suggest a possible role of hypogammaglobulinemia in reducing Ab response in patients treated with antiCD20 therapies.

Indexed as

AgammaglobulinemiaCOVID-19COVID-19 VaccinesMultiple SclerosisSevere acute respiratory syndrome-related coronavirusAntibody FormationHumansVaccinationCOVID-19 VaccinesAntiCD20COVID-19HypogammaglobulinemiaMultiple sclerosisVaccination

Identifiers

PMID35918574
PMCPMC9345744
OpenAlexW4289516994

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.